Skip to main content
Hospitalized Chronic Pain Patient A Multidisciplinary Treatment Guide

NMDA Antagonists

Publication ,  Chapter
Kent, M; Edwards, DA
January 1, 2022

Ketamine is a useful NMDA receptor antagonist that provides a strong analgesic effect even at sub-anesthetic doses, and has an established role in both acute and chronic pain management. Intravenous ketamine infusions should be considered early for pain complaints in hospitalized chronic pain patients, and is particularly useful in patients with a tolerance to opioids, neuropathic pain, or evidence of central sensitization. Side effects are typically dose dependent; significant side effects are rare. Mild psychomimetic effects may occur but quickly dissipate with cessation of infusion and are generally temporized by concurrent use of benzodiazepines. Memantine is another NMDA antagonist taken orally for the treatment of Alzheimer’s disease. Memantine has been used off-label for acute and chronic pain indications.

Duke Scholars

DOI

Publication Date

January 1, 2022

Start / End Page

175 / 177
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kent, M., & Edwards, D. A. (2022). NMDA Antagonists. In Hospitalized Chronic Pain Patient A Multidisciplinary Treatment Guide (pp. 175–177). https://doi.org/10.1007/978-3-031-08376-1_32
Kent, M., and D. A. Edwards. “NMDA Antagonists.” In Hospitalized Chronic Pain Patient A Multidisciplinary Treatment Guide, 175–77, 2022. https://doi.org/10.1007/978-3-031-08376-1_32.
Kent M, Edwards DA. NMDA Antagonists. In: Hospitalized Chronic Pain Patient A Multidisciplinary Treatment Guide. 2022. p. 175–7.
Kent, M., and D. A. Edwards. “NMDA Antagonists.” Hospitalized Chronic Pain Patient A Multidisciplinary Treatment Guide, 2022, pp. 175–77. Scopus, doi:10.1007/978-3-031-08376-1_32.
Kent M, Edwards DA. NMDA Antagonists. Hospitalized Chronic Pain Patient A Multidisciplinary Treatment Guide. 2022. p. 175–177.

DOI

Publication Date

January 1, 2022

Start / End Page

175 / 177